Lung cancer in Berlin - NET of the lung; analysis of subgroups and impact on survival (2000 - 2008)
Christian Gogoll(St. Hedwig-Krankenhaus), Anita Jagota(Zentrum Überleben), Christel Lauer(Helios Klinikum Emil von Behring), Gunda Leschber, Wulf Pankow(German Respiratory Society), Paul Schneider(DRK Kliniken Berlin), Stephan Eggeling(Vivantes Klinikum), Jens Neudecker(Humboldt-Universität zu Berlin), Torsten Blum(MSB Medical School Berlin), Nicolas Schoenfeld(Helios Klinikum Emil von Behring), Christian Witt(Heidelberg University), Christian Grohé(DRK Kliniken Berlin), B Schicke(Zentrum Überleben)
European Respiratory Journal
September 1, 2013
Cited by 0
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
|The Lancet Respiratory Medicine|2021|523
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
|Journal of Clinical Oncology|2023|386